Tags

Type your tag names separated by a space and hit enter

Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy.
Circulation. 2005 Nov 08; 112(19):2980-5.Circ

Abstract

BACKGROUND

Vasodilatory therapy of Raynaud's phenomenon represents a difficult clinical problem because treatment often remains inefficient and may be not tolerated because of side effects.

METHODS AND RESULTS

To investigate the effects of sildenafil on symptoms and capillary perfusion in patients with Raynaud's phenomenon, we performed a double-blinded, placebo-controlled, fixed-dose, crossover study in 16 patients with symptomatic secondary Raynaud's phenomenon resistant to vasodilatory therapy. Patients were treated with 50 mg sildenafil or placebo twice daily for 4 weeks. Symptoms were assessed by diary cards including a 10-point Raynaud's Condition Score. Capillary flow velocity was measured in digital nailfold capillaries by means of a laser Doppler anemometer. While taking sildenafil, the mean frequency of Raynaud attacks was significantly lower (35+/-14 versus 52+/-18, P=0.0064), the cumulative attack duration was significantly shorter (581+/-133 versus 1046+/-245 minutes, P=0.0038), and the mean Raynaud's Condition Score was significantly lower (2.2+/-0.4 versus 3.0+/-0.5, P=0.0386). Capillary blood flow velocity increased in each individual patient, and the mean capillary flow velocity of all patients more than quadrupled after treatment with sildenafil (0.53+/-0.09 versus 0.13+/-0.02 mm/s, P=0.0004). Two patients reported side effects leading to discontinuation of the study drug.

CONCLUSIONS

Sildenafil is an effective and well-tolerated treatment in patients with Raynaud's phenomenon.

Authors+Show Affiliations

Klinik für Innere Medizin III (Kardiologie, Angiologie, Internistische Intensivmedizin), Universitätsklinikum des Saarlandes, Homburg/Saar, Germany. r.fries@gotthard-schettler-klinik.deNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Controlled Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16275885

Citation

Fries, Roland, et al. "Sildenafil in the Treatment of Raynaud's Phenomenon Resistant to Vasodilatory Therapy." Circulation, vol. 112, no. 19, 2005, pp. 2980-5.
Fries R, Shariat K, von Wilmowsky H, et al. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation. 2005;112(19):2980-5.
Fries, R., Shariat, K., von Wilmowsky, H., & Böhm, M. (2005). Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation, 112(19), 2980-5.
Fries R, et al. Sildenafil in the Treatment of Raynaud's Phenomenon Resistant to Vasodilatory Therapy. Circulation. 2005 Nov 8;112(19):2980-5. PubMed PMID: 16275885.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. AU - Fries,Roland, AU - Shariat,Kaveh, AU - von Wilmowsky,Hubertus, AU - Böhm,Michael, PY - 2005/11/9/pubmed PY - 2006/3/3/medline PY - 2005/11/9/entrez SP - 2980 EP - 5 JF - Circulation JO - Circulation VL - 112 IS - 19 N2 - BACKGROUND: Vasodilatory therapy of Raynaud's phenomenon represents a difficult clinical problem because treatment often remains inefficient and may be not tolerated because of side effects. METHODS AND RESULTS: To investigate the effects of sildenafil on symptoms and capillary perfusion in patients with Raynaud's phenomenon, we performed a double-blinded, placebo-controlled, fixed-dose, crossover study in 16 patients with symptomatic secondary Raynaud's phenomenon resistant to vasodilatory therapy. Patients were treated with 50 mg sildenafil or placebo twice daily for 4 weeks. Symptoms were assessed by diary cards including a 10-point Raynaud's Condition Score. Capillary flow velocity was measured in digital nailfold capillaries by means of a laser Doppler anemometer. While taking sildenafil, the mean frequency of Raynaud attacks was significantly lower (35+/-14 versus 52+/-18, P=0.0064), the cumulative attack duration was significantly shorter (581+/-133 versus 1046+/-245 minutes, P=0.0038), and the mean Raynaud's Condition Score was significantly lower (2.2+/-0.4 versus 3.0+/-0.5, P=0.0386). Capillary blood flow velocity increased in each individual patient, and the mean capillary flow velocity of all patients more than quadrupled after treatment with sildenafil (0.53+/-0.09 versus 0.13+/-0.02 mm/s, P=0.0004). Two patients reported side effects leading to discontinuation of the study drug. CONCLUSIONS: Sildenafil is an effective and well-tolerated treatment in patients with Raynaud's phenomenon. SN - 1524-4539 UR - https://www.unboundmedicine.com/medline/citation/16275885/Sildenafil_in_the_treatment_of_Raynaud's_phenomenon_resistant_to_vasodilatory_therapy_ L2 - http://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.104.523324?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -